HCK
ENSG00000101336
Target class
Kinase
Chromosome
20
Approved drugs
2
Clinical candidates (approved and in development)
6
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Other names
- JTK9
- Target name
- HCK
- Gene name
- HCK proto-oncogene, Src family tyrosine kinase
- Gene symbol
- HCK
- Protein name
- Tyrosine-protein kinase HCK (EC 2.7.10.2) (Hematopoietic cell kinase) (Hemopoietic cell kinase) (p59-HCK/p60-HCK) (p59Hck) (p61Hck)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 545.06
- Tissue specificity (Gini)
- 0.785
- Tissue specificity (tau)
- 0.981
- KEGG gene identifiers
- hsa:3055
- Protein interaction confidence
- 0.836857
- Protein interaction partners
- 70
- R-HSA-164944
- R-HSA-2029481
- R-HSA-912631
- R-HSA-9664323
- R-HSA-9664422
- R-HSA-9674555
- R-HSA-9680350
- R-HSA-9705462
- R-HSA-9706374
- End position
- 32101856
- Start position
- 32052197
- Chromosome
- 20
- Strand
- Forward
- [Isoform 1]: Lysosome. Membrane
- Lipid-anchor. Cell projection, podosome membrane
- Lipid-anchor. Cytoplasm, cytosol. Note=Associated with specialized secretory lysosomes called azurophil granules. At least half of this isoform is found in the cytoplasm, some of this fraction is myristoylated.
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Lipid-anchor . Membrane, caveola
- Lipid-anchor . Cell junction, focal adhesion . Cytoplasm, cytoskeleton . Golgi apparatus . Cytoplasmic vesicle . Lysosome . Nucleus . Note=20% of this isoform is associated with caveolae. Localization at the cell membrane and at caveolae requires palmitoylation at Cys-3. Colocalizes with the actin cytoskeleton at focal adhesions.
- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle. Cytoplasm, cytosol.
- Cytosol
- Plasma membrane
- Vesicles
Publication evidence
- PubMed 11904303
- Tissue specificity (tau)
- 0.98098
- Expression inequality (Gini)
- 0.784869
Expression in transcripts per million
- Whole Blood
- 545.06
- Spleen
- 182.77
- Lung
- 60.42
- Adipose - Visceral (Omentum)
- 18.98
- Small Intestine - Terminal Ileum
- 18.1
Expression in transcripts per million
- Whole Blood545.06
- Spleen182.77
- Lung60.42
- Adipose - Visceral (Omentum)18.98
- Small Intestine - Terminal Ileum18.1
- Adipose - Subcutaneous16.18
- Cells - EBV-transformed lymphocytes14.94
- Artery - Coronary13.54
- Artery - Aorta12.77
- Nerve - Tibial12.5
- Brain - Spinal cord (cervical c-1)10.73
- Adrenal Gland10.49
- Colon - Transverse10.43
- Bladder9.03
- Breast - Mammary Tissue8.73
- Fallopian Tube7.98
- Cervix - Endocervix7.49
- Prostate6.53
- Vagina6.52
- Colon - Sigmoid6.17
- Minor Salivary Gland5.92
- Esophagus - Muscularis5.77
- Artery - Tibial5.54
- Skin - Sun Exposed (Lower leg)5.3
- Brain - Substantia nigra5.26
And 29 more, listed on the interactive page.
- GO:0002522
- GO:0002758
- GO:0002862
- GO:0006468
- GO:0007155
- GO:0007229
- GO:0007498
- GO:0008284
- GO:0008360
- GO:0018108
- GO:0019221
- GO:0030838
- GO:0031663
- GO:0032956
- GO:0035556
- GO:0038096
- GO:0043066
- GO:0043299
- GO:0045728
- GO:0046777
- GO:0050727
- GO:0050764
- GO:0060333
- GO:0071801
- GO:0005764
- GO:0005829
- GO:0005884
- GO:0005886
- GO:0005901
- GO:0005925
- GO:0009898
- GO:0001784
- GO:0004713
- GO:0005515
- GO:0008289
Related records
Trials (750)
- A Bioequivalence Study of Dasatinib Tablet
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Drugs (10)
- Bosutinib Tyrosine-protein kinase HCK inhibitor
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- Pexmetinib
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor